Healthcare · NSE/BSE: SYNGENE
Syngene International Limited
Healthcare Research, Analytics & Technology
Market Cap ₹0.18L Cr
Verdict: Average
Quality Scores
Multi-Bagger
45/100
Compounder Quality
72/100
Management Credibility
75/100
Governance
92/100
Cash Flow Quality
90/100
AI Summary
Syngene International Limited, a subsidiary of Biocon, is a premier integrated Contract Research and Manufacturing Services (CRAMS) provider in India. Over the last decade, it has evolved from a pure-play CRO into a multi-disciplinary partner for 13 of the top 15 global pharma companies. While the company maintains a robust infrastructure of 1.9 million sq. ft. and over 6,000 scientists, recent financial performance has entered a decelerating phase. Market capitalization stands at approximately ₹18,117 Cr, but growth metrics for the last 3-5 years indicate a cooling of the earlier high-growth…
Top Opportunities
- Reduced debt consistently
- Almost debt-free balance sheet
- Strong client base including 13 of top 15 global pharma
Top Risks
- Significant margin erosion in most recent years
- Poor sales growth over the last 3-5 years
- Low Return on Equity (ROE) trending downwards
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.